

Special Issue

Recent Advances in Protein-Drug Conjugates: From Bioanalytical, Drug Metabolism to Pharmacokinetics

Message from the Guest Editor

Protein–drug conjugates such as antibody–drug conjugates (ADC) have recently received significant attention due to their dramatic clinical efficacies with acceptable toxicity profiles, particularly as novel anticancer drugs. This approach comprises a protein (i.e., monoclonal antibody) conjugated to the cytotoxic payload via a chemical linker directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and, therefore, toxicity. Thus, ADC is one of the most popular platforms but also requires a good balance among various components such as monoclonal antibody, linker, and payload from drug metabolism and pharmacokinetic perspectives. Albumin–drug conjugates (ALDCs) are another good novel platform of choice due to favorable distribution to the tumor as well as a long half-life. ALDCs are also receiving increased attention from the pharmaceutical industry as an alternative approach to overcome various cancers. In addition to protein or linker sides, new payloads are also recently introduced, such as immuno-modulators, molecular glues, and PROTACs for conjugation.

Guest Editor

Prof. Dr. Young G. Shin

College of Pharmacy and Institute of Drug Research and Development,
Chungnam National University, Daejeon, Republic of Korea

Deadline for manuscript submissions

closed (15 March 2024)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/161514

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).